Companies / Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

Nasdaq: NEUPCIK 1191070BURLINGTON, MA

Financials · FY2025

Revenue$15.65M
Net income$-369.6K
Total debt—
Cash$19.44M
Diluted EPS$-0.23
Shares outstanding5.4M

Ownership

5.4M shares outstanding · as of May 14, 2026
30.4%Institutions
Ownership
Institutions30.40%1,642,886
Public float69.60%3,761,665

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Davies Peter Miles WinstonDirector
——
Fisher AlanDirector
——
Ryan JaneDirector
——
Wilson David IanDirector
——

Institutional holders 22

View all →
HolderValue% of shares
Lynx1 Capital Management LP$3.40M16.19%
Shay Capital LLC$655.9K3.13%
Balyasny Asset Management L.P.$578.7K2.63%
AdvisorShares Investments LLC$520.7K2.48%
Geode Capital Management, LLC$211.7K0.96%
Diadema Partners LP$194.0K0.93%
Ikarian Capital, LLC$184.1K0.88%
ADAR1 Capital Management, LLC$116.4K0.56%
Vanguard Group Inc$81.3K0.39%
Jane Street Group, LLC$64.4K0.31%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 20, 2026Wilson David Ian
Director
GrantRestricted Stock Units—+9K
+124.17%
15,412
0.29% of shares
low
Jan 20, 2026Fisher Alan
Director
GrantRestricted Stock Units—+17K
+125.00%
30,731
0.57% of shares
low
Jan 20, 2026Davies Peter Miles Winston
Director
GrantRestricted Stock Units—+9K
+125.86%
15,320
0.28% of shares
low
Jan 20, 2026Ryan Jane
Director
GrantRestricted Stock Units—+9K
+121.73%
15,550
0.29% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Baselake Partners, LPPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
NEUPCommon StockEquity64136E102BBG01RFZ8658